Generating transgenic models via in-vitro selection of embryonic stem clones:; an accelerated route to in-vivo disease models and target validation

Summary Techniques to customize and predict transgenic animal phenotype through in-vitro pre-screening would be highly advantageous. Research from the lab of Professor David Sinclair presents a new platform for generating transgenic animals using a series of in-vitro screening techniques and a library of embryonic stem (ES) cell clones. Key improvements over the prior art include methods for exposing ES cell clones to various conditions and agents, screening for specific ES cell phenotypes, and using results to predict subsequent transgenic animal phenotypes. The technique of producing “ES mice” from ES cells, subjected to multiple rounds of in vitro selection, has demonstrated high efficiency and the potential to short-cycle transgenic animal development.

Applications The invention is broadly relevant to generating transgenic animals for drug target validation and preclinical compound development. There exists a growing market for animal models that better predict human disease and provide crucial insights pertinent to compound toxicity and efficacy. New animal models of the invention may address a variety of diseases, including neurodegenerative disease, cancer, diabetes, and metabolic disease. For Further Information Please Contact the Director of Business Development Michal Preminger Email: [email protected] Telephone: (617) 432-0920

Type of Offer: Licensing



« More Pharmaceutical Patents

---